• Users Online:999
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 15  |  Issue : 2  |  Page : 77-94

Homoeopathic pathogenetic trial of Cuprum aceticum: A multicentric, double-blind, randomized, placebo controlled trial


1 D. P. Rastogi Central Research Institute of Homoeopathy, Noida, India
2 Central Research Institute of Homoeopathy, Jaipur, Rajasthan, India
3 Regional Research Institute of Homoeopathy, Gudivada, Andhra Pradesh, India
4 Homoeopathic Drug Research Institute, Lucknow, Uttar Pradesh, India
5 Central Council for Research in Homoeopathy, New Delhi, India

Correspondence Address:
Dr. Ashish Mahajan
Central Research Institute of Homoeopathy, Sector- 26, Pratap Nagar, Jaipur - 302 033, Rajasthan
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijrh.ijrh_54_20

Rights and Permissions

Background: Although the symptomatology of Cuprum metallicum is quite vast, its other salts have fragmentary proving. Thus, homoeopathic pathogenetic trial for Cuprum aceticum (Cu acet.) was taken up. Objective: To elicit the pathogenetic response to Cu acet. in homoeopathic potencies on healthy human provers. Materials and Methods: A multi-center, double-blind randomized, placebo controlled, trial was conducted at three centers of Central Council for Research in Homoeopathy. Proving was conducted on 50 relatively healthy provers selected after conducting the Pretrial Medical Examination. All the provers were given placebo during the first phase of the trial. In the next two phases, Cu acet. was administered in 6 C and 30 C potencies, in the intervention group (n = 34); and placebo in the placebo group (n = 16), after randomization. The proving data so generated on Cu acet. were compiled and analyzed at the proving-cum-data processing cell. Results: Out of 34 provers who were on actual drug trial, only 12 provers manifested symptoms. Twenty-six and 20 symptoms were manifested in 6C and 30C potency, respectively. Conclusion: The pathogenetic response elicited during the proving trial expands the scope of use of the homoeopathic medicine C. aceticum. The symptoms generated in this trial will carry more value when verified clinically.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1568    
    Printed28    
    Emailed0    
    PDF Downloaded343    
    Comments [Add]    

Recommend this journal